vedolizumab
takeda
[' vedo', 'ibd', 'vedo', 'crohn', 'vedolizumab']
the primary endpoint was endoscopic recurrence of crohn s disease; patients in the vedolizumab group had a 77.8% chance of having a lower rutgeert s score than those in the placebo group; no new safety signals in the immediate post op period #ibd #gitwitter #ecco2023 #ecco23 
The Lancet Gastroenterology & Hepatology is the world-leading #gastroenterology and #hepatology research journal. IF=45.042. #Lancet200